NSE filing, NSE: BALAXI. Summary written from the filing by ALFA Finder's alert engine.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹20.33
- Market cap
- ₹112.2 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 46.3×Sector 46.1×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Board Meeting Date
Balaxi Pharmaceuticals will meet on 12 November 2026 to approve unaudited half-year results. The trading window stays closed until 14 November 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Other annual general meeting announcements
All →Tasty Bite Eatables Annual General Meeting
Tasty Bite Eatables declared postal ballot results approving a material related-party transaction with Mars Food UK Limited for purchase of a capital asset. Promoter group did not vote and the resolution passed with 99.99% of votes cast in favour.
Unihealth Hospitals Annual General Meeting
Unihealth Hospitals reported postal ballot results: all three resolutions passed, covering a related-party loan-to-equity conversion with UMC Hospitals, variation of unutilised IPO proceeds, and migration from NSE Emerge to the main board. No rupee amount is stated for the approvals.
Vedanta Iron and Steel Annual General Meeting
Vedanta Iron and Steel seeks shareholder approval via postal ballot for seven material related party transaction resolutions. E-voting runs from 29 October to 27 November 2026.
GTPL Hathway Annual General Meeting
GTPL Hathway seeks shareholder approval by postal ballot to appoint Gurjeev Singh Kapoor as Non-Executive Director. E-voting runs November 1 to 30, 2026.
HEG Advanced Materials Annual General Meeting
HEG Advanced Materials seeks approval via postal ballot to appoint seven directors and fix MD Riju Jhunjhunwala's remuneration. E-voting runs October 29 to November 27, 2026.
Trident Texofab Annual General Meeting
Trident Texofab's EGM on 28 October 2026 sought approval for a statutory auditor to fill a casual vacancy. Only one ordinary resolution was tabled.